Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy ...

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

Viridian plans to initiate the THRIVE-2 Phase 3 trial to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED in Q3 2023, with topline data expected by the end of 2024.

WALTHAM, Mass., May 30, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for ...

Viridian has released phase 1/2 data on a small group of patients that suggests its thyroid eye disease candidate could rival Amgen-acquired Horizon.

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

Viridian said this week that it is on track to report the phase 3 results from REVEAL-1 and REVEAL-2 trials of VRDN-003 in active and chronic TED patients in the first half of 2026, and I believe ...

Viridian's thyroid eye disease drug veligrotug clears its first phase 3 trial, with data suggesting it could be competitive with Amgen's Tepezza.

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...